New Delhi, July 18 -- The Indian pharmaceutical sector is expected to maintain a healthy growth trajectory in the coming quarters, supported by sustained domestic demand, a recovery in Contract Development and Manufacturing Organization/ Active Pharmaceutical Ingredient segment activity and expanding opportunities in GLP-1 therapies, even as the US business remains under pressure and input-cost risks persist, according to a report by 360 ONE Capital.

The brokerage expects the sector to deliver 10 per cent year-on-year revenue growth in 1QFY27, with domestic and Contract Development and Manufacturing Organization/ Active Pharmaceutical Ingredient segments growing 12.7 per cent and 9.9 per cent, respectively. However, the US business is pr...